Online citations, reference lists, and bibliographies.

The Current Management Of Cancer Cachexia

G. Mantovani
Published 2006 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The anorexia/cachexia syndrome is one of the most common causes of death among patients with cancer and is present in 80% at death [1]. The term ‘cachexia’ derives from the Greek kakos, which means ‘bad’, and hexis, meaning ‘condition’. The characteristic clinical picture of anorexia, tissue wasting, loss of body weight accompanied by a decrease in muscle mass and adipose tissue, and poor performance status that often precedes death has been named cancer-related anorexia/cachexia (CAC) [2] [5]. Since the 1980s, the previous concepts explaining CAC were replaced by a more complex insight, which stresses the interaction between metabolically active molecules produced by the tumour itself and the host immune response. One of the main features of the cachectic syndrome is anorexia, which may be so significant that spontaneous nutrition is totally inhibited. The pathogenesis of anorexia is most certainly multifactorial but not yet well understood.
This paper references
Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover.
S. A. Beck (1991)
10.1007/978-3-642-78217-6
Growth Hormone and Somatomedins during Lifespan
E. E. Müller (1993)
Pharmacologic management of anorexia/cachexia.
F. Ottery (1998)
10.1084/jem.172.1.391
Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway
J. Han (1990)
10.1097/00075197-199907000-00016
Metabolic sequelae of cancers (excluding bone marrow transplantation).
J. Body (1999)
10.1016/0899-9007(95)00066-6
Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia.
M. Tisdale (1996)
10.1126/science.7624777
Weight-reducing effects of the plasma protein encoded by the obese gene.
J. Halaas (1995)
10.1016/0026-0495(87)90068-0
Metabolic efficacy of enteral feeding in malnourished cancer and noncancer patients.
C. Dresler (1987)
10.1146/annurev.ph.47.030185.002303
Actions of insulin-like growth factors.
E. Froesch (1985)
10.1016/0304-3835(96)04247-4
Prolongation of survival period and improvement of cancer cachexia by long-term administration of UFT.
M. Nukatsuka (1996)
10.1172/JCI116537
Immunologic effects of national cholesterol education panel step-2 diets with and without fish-derived N-3 fatty acid enrichment.
S. Meydani (1993)
10.1016/0166-6851(80)90046-8
Hypertriglyceridemia associated with Trypanosoma brucei brucei infection in rabbits: role of defective triglyceride removal.
C. Rouzer (1980)
10.1007/s00520-001-0310-7
Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation
A. Jatoi (2001)
10.1200/JCO.1994.12.6.1121
Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer.
C. L. Loprinzi (1994)
10.1038/bjc.1993.202
A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia.
S. Downer (1993)
10.1016/S0899-9007(96)00313-9
Cancer cachexia: metabolic alterations and clinical manifestations.
M. Tisdale (1997)
Megestrol acetate in cancer cachexia.
E. Schmoll (1991)
Uncomplicated starvation versus cancer cachexia.
M. Brennan (1977)
10.1016/S1040-8428(00)00048-2
Nutritional support of the cancer patient: issues and dilemmas.
G. Nitenberg (2000)
10.1093/jnci/82.24.1922
Lipolytic factors associated with murine and human cancer cachexia.
S. A. Beck (1990)
10.1038/bjc.1997.463
A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients.
D. McMillan (1997)
10.1152/ajpcell.1987.253.6.C766
Interleukin 1 and tumor necrosis factor do not regulate protein balance in skeletal muscle.
L. Moldawer (1987)
10.1200/JCO.1996.14.1.135
Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study.
K. Rowland (1996)
10.1200/JCO.20.2.567
Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study.
A. Jatoi (2002)
10.1016/S0304-3835(97)04718-6
Comparative effects of beta2-adrenergic agonists on muscle waste associated with tumour growth.
N. Carbó (1997)
10.1210/jcem.80.7.7608259
Failure of anabolism in malnourished cancer patients receiving growth hormone: a clinical research center study.
J. Tayek (1995)
10.1097/00000658-197410000-00031
Catecholamines: Znediator of the Hypermetabolic Response to Thermal Injury
D. Wilmore (1974)
10.1097/00000421-199210000-00008
Usefulness of Megestrol Acetate in Cancer Cachexia and Anorexia: A Placebo‐Controlled Study
J. Feliu (1992)
10.1016/0031-9384(92)90475-H
Food intake and body temperature responses of rats to recombinant human interleukin-1β and a tripeptide interleukin-1β antagonist
C. L. McLaughlin (1992)
10.1038/bjc.1994.161
Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines.
J. Falconer (1994)
10.1016/0261-5614(94)90065-5
Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients.
D. McMillan (1994)
10.1093/ajcn/30.8.1301
Energy balance and carbohydrate metabolism in infection and sepsis.
C. Long (1977)
10.1200/JCO.1993.11.4.762
Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia.
C. Loprinzi (1993)
10.1016/0899-9007(95)00078-X
The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer.
S. Wigmore (1996)
10.1177/082585979300900105
Assessment of Upper Gastrointestinal Motility in the Cancer–Associated Dyspepsia Syndrome
K. Nelson (1993)
10.1016/0277-5379(89)90353-2
Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group.
G. R. della Cuna (1989)
10.1016/S1357-4310(98)01395-1
Neuropeptide Y: a key molecule in anorexia and cachexia in wasting disorders?
A. Inui (1999)
10.1159/000227125
Treatment of cancer weight loss in patients with advanced lung cancer.
M. Heckmayr (1992)
10.1200/JCO.2004.06.024
An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort.
A. Jatoi (2004)
10.1002/1097-0142(19900615)65:12<2657::AID-CNCR2820651210>3.0.CO;2-S
A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia
Carl G. Kardinal (1990)
10.1016/0277-5379(89)90354-4
Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group.
T. Popiela (1989)
10.1177/014860719802200118
Role of nutrition support during induction chemoradiation therapy in esophageal cancer.
S. Sikora (1998)
10.1200/JCO.1995.13.11.2856
Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial.
R. Goldberg (1995)
Supportive nutritional management of the patient with pancreatic cancer.
F. Ottery (1996)
10.1016/S0959-8049(96)00309-7
Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy.
R. Fietkau (1997)
10.1084/jem.169.1.333
The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome
A. Waage (1989)
10.1002/1097-0142(19941215)74:12<3204::AID-CNCR2820741220>3.0.CO;2-G
Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer
E. Bruera (1994)
10.1093/jnci/82.13.1127
Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia.
C. Loprinzi (1990)
10.1001/jama.1987.03390090067026
High-dose megestrol acetate. A possible treatment for cachexia.
N. S. Tchekmedyian (1986)
10.1136/bmj.288.6410.27
Prednisolone as an appetite stimulant in patients with cancer.
J. Willox (1984)
Intolerance to administered lipids in tumor-bearing animals.
D. Devereux (1984)
10.1002/1097-0142(197406)33:6<1607::AID-CNCR2820330620>3.0.CO;2-V
Corticosteroid therapy of preterminal gastrointestinal cancer
C. Moertel (1974)
10.1038/379739a0
Characterization of a cancer cachectic factor
P. Todorov (1996)
10.1016/S0016-5085(83)80234-0
Metabolic response of whole body and peripheral tissues to enteral nutrition in weight-losing cancer and noncancer patients.
K. Bennegȧrd (1983)
10.1126/science.7624778
Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks.
L. A. Campfield (1995)
10.1200/JCO.1994.12.1.213
The cancer anorexia-cachexia syndrome.
K. Nelson (1994)
10.1007/BF02592554
Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy
G. Mantovani (1995)
Role of medroxyprogesterone in endocrine-related tumors
S. Iacobelli (1980)
10.1016/0960-7404(94)90027-2
Tumor necrosis factor and cachexia: a current perspective.
N. Espat (1994)
10.1016/0092-8674(87)90028-6
Tumors secreting human TNF/cachectin induce cachexia in mice
A. Oliff (1987)
10.1152/ajpregu.1991.260.2.R321
Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism.
C. Billington (1991)
10.1097/00000658-198312000-00011
Free Fatty Acid Mobilization and Oxidation During Total Parenteral Nutrition in Trauma and Infection
J. Nordenström (1983)
Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study.
E. Bruera (1998)
10.1001/archsurg.1983.01390020023004
Exchange of amino acids by muscle and liver in sepsis.
Szymon S. Rosenblatt (1983)
10.1056/NEJM198110153051601
Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.
R. Gralla (1981)
10.1007/s001090000137
Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites
G. Mantovani (2000)
10.1007/978-3-642-78217-6_27
Anabolic Effects of Growth Hormone Administration in Adults
T. Ziegler (1993)
10.1023/A:1008291825695
Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial
E. Beller (1997)
10.1097/00000421-198602000-00020
Cancer : Principles and Practice of Oncology
V. Devita (1982)
Cancer anorexia-cachexia syndrome: are neuropeptides the key?
A. Inui (1999)
10.1007/BF02535969
Effects of an eicosapentaenoic and docosahexaenoic acid concentrate on a human lung carcinoma grown in nude mice
M. G. Bravo (2006)
10.1016/0002-9610(83)90067-3
Tumor-associated gastroparesis: correction with metoclopramide.
K. Shivshanker (1983)
10.1097/01.mco.0000172581.79266.19
Branched-chain amino acids: the best compromise to achieve anabolism?
A. Laviano (2005)
10.1177/014860719201600602
The role of cytokines in cancer cachexia.
L. Moldawer (1992)
10.1200/jco.1984.2.5.414
Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
F. Cavalli (1984)
10.1152/ajpregu.1999.277.3.R850
Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats.
G. Torelli (1999)
Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study.
E. Bruera (1985)
10.1016/S0261-5614(97)80006-4
Nutrition support in clinical practice: review of published data and recommendations for future research directions. National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition.
S. Klein (1997)
10.1200/JCO.1994.12.6.1126
Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer.
C. Loprinzi (1994)
Acute central effects of interleukin-6 on body temperature, thermogenesis and food intake in the rat
Busbridge Nj (1989)
10.1016/S0959-8049(96)00486-8
Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients.
G. Mantovani (1997)
10.1016/S0140-6736(89)92929-2
OXPENTIFYLLINE IN ENDOTOXAEMIA
P. Zabel (1989)
10.1002/(SICI)1097-0142(19970501)79:9<1828::AID-CNCR28>3.0.CO;2-Z
Proinflammatory cytokines, nutritional support, and the cachexia syndrome
L. Moldawer (1997)
10.1016/S0899-9007(96)80061-X
Nutritional issues in cancer management.
A. Laviano (1996)
Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide.
E. Bruera (1983)
10.1093/JNCI/90.23.1766
Can reducing caloric intake also help reduce cancer?
M. Miller (1998)
10.1136/gut.2004.047563
Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial
J. Gordon (2005)
10.1096/fasebj.3.8.2721856
Anticachectin/tumor necrosis factor‐α antibodies attenuate development of cachexia in tumor models
B. Sherry (1989)
10.1152/ajpregu.1989.257.3.R613
Anorexia induced by interleukin 1: involvement of corticotropin-releasing factor.
A. Uehara (1989)
10.1038/bjc.1995.300
Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients.
S. Wigmore (1995)
10.1152/ajpendo.1992.262.5.E728
Sepsis-induced cascade of cytokine mRNA expression: correlation with metabolic changes.
L. Byerley (1992)
10.1016/0959-8049(96)00136-0
Is there a role for melatonin in the treatment of neoplastic cachexia?
P. Lissoni (1996)
10.1016/0885-3924(94)90200-3
Corticosteroids as adjuvant analgesics.
S. Watanabe (1994)
10.1042/cs0870711
Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer.
P. Purasiri (1994)
10.1002/1097-0142(19861015)58:8+<1867::AID-CNCR2820581413>3.0.CO;2-A
Pathophysiology of malnutrition in the adult cancer patient
D. Heber (1986)
10.1002/1097-0142(19890115)63:2<330::AID-CNCR2820630221>3.0.CO;2-U
Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration
M. Grosvenor (1989)
10.1093/JNCI/89.23.1763
Biology of cachexia.
M. Tisdale (1997)
10.1007/978-3-642-84734-9_65
Measuring the severity of injury.
H. Stoner (1977)
10.1111/j.1365-2265.1995.tb02603.x
Megestrol‐induced Cushing's syndrome
K. Steer (1995)
10.1002/1097-0142(19900915)66:6<1279::AID-CNCR2820660630>3.0.CO;2-R
A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer
E. Bruera (1990)
Inhibition by hydrazine of gluconeogenesis in the rat.
P. Ray (1970)
Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor.
K. Kishi (2000)
10.1016/S0140-6736(74)92290-9
HYPERGLUCAGONÆMIA AFTER BURNS
D. Wilmore (1974)
Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.
M. Trikha (2003)
10.1177/082585979401000105
A Phase II Study of Delta-9-Tetrahydrocannabinol for Appetite Stimulation in Cancer-Associated Anorexia
K. Nelson (1994)
10.1093/JN/129.6.1120
Fish oil-enriched nutritional supplement attenuates progression of the acute-phase response in weight-losing patients with advanced pancreatic cancer.
M. Barber (1999)
10.1016/S0899-9007(96)00164-5
Cracking the riddle of cancer anorexia.
A. Laviano (1996)
10.1016/0014-2999(94)90229-1
Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations.
H. McCarthy (1994)
10.1016/0885-3924(94)00117-4
Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS.
J. E. Beal (1995)
10.1097/01.COC.0000074180.16144.B3
COX-2 Inhibitors and Cancer Therapeutics: Potential Roles for Inhibitors of COX-2 in Combination With Cytotoxic Therapy: Reports From a Symposium Held in Conjunction With the Radiation Therapy Oncology Group June 2001 Meeting
A. Dicker (2003)
Identification of a human tumor-derived lipolysis-promoting factor.
D. D. Taylor (1992)
10.1016/S0899-9007(97)00185-8
Cytokines and cachexia.
P. Matthys (1997)
Effects of tumor type and burden on carcass lipid depletion in mice.
D. Hollander (1986)
10.1038/bjc.1996.297
Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer.
V. Gebbia (1996)
10.1016/S0889-8588(18)30456-8
Clinical trials of nutritional support in cancer. Parenteral and enteral therapy.
T. Lipman (1991)
10.1111/j.1365-2362.1994.tb01089.x
Neuropeptide Y and energy balance: one way ahead for the treatment of obesity?
S. Dryden (1994)
10.1016/S0195-6663(88)80017-5
Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory
R. Foltin (1988)
10.1093/jnci/85.5.365
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
N. Aaronson (1993)
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.
J. Masferrer (2000)
10.1055/s-2007-1012410
Reduced plasma lipoprotein lipase activity in patients with malignancy-associated weight loss.
H. Vlassara (1986)
10.1042/cs0920215
Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6.
S. Wigmore (1997)
10.1038/377530a0
The role of neuropeptide Y in the antiobesity action of the obese gene product
T. W. Stephens (1995)
10.1097/00001622-199907000-00004
The syndrome of anorexia-cachexia.
J. Body (1999)
10.1136/gut.52.10.1479
Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial
K. Fearon (2003)
Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia.
J. Gelin (1991)
10.1038/bjc.1990.385
Alterations in serum lipolytic activity of cancer patients with response to therapy.
S. A. Beck (1990)
10.1152/ajpregu.1987.253.6.R922
Circulating interleukin 1 and tumor necrosis factor during inflammation.
L. Moldawer (1987)
10.1097/00000658-199701000-00012
Modulation of human hepatocyte acute phase protein production in vitro by n-3 and n-6 polyunsaturated fatty acids.
S. Wigmore (1997)
Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin.
P. Lissoni (1994)
10.1172/JCI115767
Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
G. Strassmann (1992)
10.1016/0361-9230(91)90055-O
Dexamethasone inhibits food intake suppression induced by low doses of interleukin-1 β administered intracerebroventricularly
C. Plata-salamán (1991)
10.1200/JCO.1996.14.4.1077
Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study.
J. Simons (1996)
Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors.
K. Lundholm (1994)
10.1200/JCO.1994.12.6.1113
Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B.
M. Kosty (1994)
10.1002/CNCR.2820690532
Megestrol acetate in cancer anorexia and weight loss
N. S. Tchekmedyian (1992)
10.1090/S0002-9939-1964-0158004-0
A note on theorems of Burnside and Blichfeldt
R. Brauer (1964)
Inhibition of tumor necrosis factor-alpha secretion by pentoxifylline in advanced cancer patients with abnormally high blood levels of tumor necrosis factor-alpha.
P. Lissoni (1993)
10.1006/cyto.1995.1003
The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo.
S. Siegel (1995)
Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
B. Reddy (2000)
10.1177/014860719201600603
Cytokines and their role in the pathophysiology of cancer cachexia.
M. McNamara (1992)
10.1016/0167-5699(94)90137-6
The acute phase response.
H. Baumann (1994)
10.1159/000227126
Clinical management of anorexia and cachexia in patients with advanced cancer.
E. Bruera (1992)
10.1152/ajpgi.1988.254.3.G450
Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines.
L. Moldawer (1988)
10.1007/BF00311551
Are cytokines possible mediators of cancer cachexia?
Y. Noguchi (2004)
Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate.
G. Mantovani (1998)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar